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Background: The purpose of this study is to evaluate the suitability of lobectomy with isthmectomy (LwI)
in treatment of Follicular Thyroid Neoplasms (FTN), considering malignancy incidence and postoperative
complications.
Methods: 192 patients (165 females; 27 males) who underwent LwI for FTN from 01/2005 to 12/2007
were retrospectively evaluated: clinical and pathological features, surgical complications and ﬁve year
outcome. Inclusion criteria were cytological Bethesda category III and IV or histological follicular ade-
noma/carcinoma or follicular variant of papillary carcinoma). Metastatic disease or previous thyroidal
surgery patients were excluded.
Results: Mean age was 48.68  14.93yrs. Overall malignancy occurred in 88 patients (45.83%) and 80
(41.67%) underwent thyroidectomy completion (TC), mainly by index lesion’s malignancy. Forty-one
(21.35%) in LwI and 31 (38.75%) in TC specimens had associated malignancy, mainly papillary micro-
carcinomas. High preoperative Thyroid-Stimulating Hormone (TSH), histological multinodularity and, in
cytology category IV, younger age, were signiﬁcantly associated to malignancy. Permanent recurrent
laryngeal nerve lesion occurred in 0.58% in Lwl and 1.52% in TC, and temporary dysphonia occurred in
9.25% and 6.06% (LwI and TC respectively). No LwI patients presented hypoparathyroidism whereas
3.03% in TC had temporary symptoms. In LwI, 36.70% developed hypothyroidism. Higher preoperative
TSH was associated with hypothyroidism development.
Conclusions: LwI was inappropriate in 40.10% patients with malignancy who required TC and 23.12% had
no functional beneﬁt because post-LwI hypothyroidism. Nodular relapse was reported in at least 23/113
LwI patients (20.35%). We propose total thyroidectomy for patients with FTN preoperative TSH higher
than 2.16 mU/L and, in Bethesda category IV, less than 39.5yrs.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Thyroid differentiated cancer is the most common endocrine
neoplasia and stands for 90% of thyroid cancers. Its incidence has
increased inwesternworld but its mortality has remained constant,
suggesting a better diagnostic accuracy.1,2 Thyroid tumors present
as nodular lesions which are highly prevalent. On physical exami-
nation, thyroid nodules are identiﬁed in 10% of patients and, by
ultrasonography, there are reports of 67%.3 However, only 5e30% of
these are malignant.4 With widespread use of Fine-Needle Aspi-
ration Biopsy (FNAB), thyroid surgery for benign pathology hasCentro Hospitalar São João,
Porto, Portugal. Tel.: þ351
ira-Gomes).
ciates Ltd. Published by Elsevier Ltdeclined signiﬁcantly. Despite a sensitivity of 83%, speciﬁcity of 92%
and a accuracy of 95%,5 there is a “gray-zone” on FNAB which
corresponds to Follicular Thyroid Neoplasms (FTN) whose uncer-
tain nature requires histological evaluation.6 FTN on FNAB can
occur in nodular goiter, follicular adenoma (FA) as well as in well
differentiated carcinomas [follicular carcinoma (FC) and follicular
variant of papillary thyroid carcinoma (FVPTC)]. The Bethesda
System for reporting thyroid cytopathology has an implied risk of
malignancy in category III of 5e15% and category IV of 15e30%.7
When FNAB revels an FTN, ﬁnal diagnosis of FC depends on histo-
logical demonstration of capsular and/or vascular invasion; deﬁn-
itive diagnosis of FVPTC depends on a cytological evaluation with a
better sample and/or histological diagnosis.8,9 Advances in molec-
ular genetics have tried to deﬁne speciﬁc mutations for each FTN.
RASmutations and t (2,3) PAX8-PPAR-gama have been found in FTN
however each mutationwas found in the different FTN with similard. All rights reserved.
Table 1
Pathological diagnosis.






n (%) n (%) n/N (%)
Benignb 102 (53.13%) 36 (18.75%) 3/102 (2.94%)c
WDTUMPd 2 (1.04%) e 0/2 (0%)
Malign 88 (45.83%) 41 (21.35%) 77/88 (87.5%)












40 (20.83%) 6 (3.125%) 38/40 (95.00%)e
Papillary carcinoma
Hurthle cell variant
27 (14.07%) 3 (1.56%) 27/27 (100%)
Classic papillary
carcinoma
1 (0.52%) 2 (1.04%) 1/1 (100%)
WDCNOSf 1 (0.52%) e 1/1 (100%)
MicroFVPTC 12 (6.25%) e 4/12 (33.33%)g
Micro PTC Hurthle
cells variant
1 (0.52%) e 0/1 (0.00%)
Classic papillary
microcarcinoma
e 30 (15.625%) e
a According to index nodule histological diagnosis.
b Benign diagnosis e FA, FA with Hurthle cells, Hurthle cells adenoma, colloid
nodule and Hashimoto thyroiditis.
c In 2 patients, TC was required by malignant associated lesion.
d Well differentiated tumor of uncertain malignant potential.
e One patient who did not underwent TC surgery had a FVPTC with 1.10 cm and
associatedbenignadenomatousnodules.TheotheronehadasolitaryFVPTCwith1.00cm.
f Well differentiated carcinoma non otherwise speciﬁed.
g TC was made by vascular invasion and/or patient desire.
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FNAB reported a sensitivity of 12%, speciﬁcity of 98%, a positive and
negative predictive value of 38% and 65%, respectively.12 So, despite
several clinical, imaging and molecular features being associated
with FTN nature, their role in therapeutic decision is yet limited,
even when combined, which makes Lobectomy with Isthmectomy
(LwI) the most accurate diagnostic procedure. Preoperative char-
acterization of FTN in a lesser invasive approach remains a chal-
lenge in endocrine pathology and a signiﬁcant controversy also
remains in the deﬁnition of the best therapeutic approach.13,14 LwI
is the minimal therapeutic procedure for patients with FTN, which
has been accepted, since FTN are usually unifocal and malignancy
risk is lesser than 30%. Patients who underwent LwI for FTN, had
cancer in 19% and this procedurewas considered adequate in 96% of
patients,15 with comparable results to total thyroidectomy (TT)
concerning recurrence and survival.16 In more advanced neoplasms
than T1N0M0, LwI had a 2.5-fold higher recurrence risk and 2.2-
fold risk of death compared with TT,17 despite a lesser complica-
tions’ rate.18,19 TT has a higher risk of permanent hypoparathy-
roidism and recurrent laryngeal nerve palsy and all patients
develop hypothyroidism requiring lifelong opotheraphy. In LwI,
opotheraphywill be required in at least 10.9% of patients, with 1 out
of 25 patients developing clinical hypothyroidism.20,21 LwI can cure
patients with FA and minimally invasive FC. It has minimal risk of
hypoparathyroidism and a lower morbidity than TT. Patients with
FC (widely invasive or angioinvasive) or FVPTC, ultimately will need
a thyroidectomy completion (TC).
The aim of the present study is to evaluate the incidence of
malignancy in patients with FTN who underwent LwI, morbidity of
procedure, need for TC, late post-operative hypothyroidism and
recurrent nodular disease.2. Patients and methods
A retrospective study was carried out based on clinical ﬁles of
patients who underwent LwI for FTN or follicular lesion of unde-
termined signiﬁcance between January 2005 andDecember 2007 in
Centro Hospitalar de São João, Porto, Portugal, after approval by
Ethical Commission Boarder. Inclusion criteria were lesions with
cytological Bethesda category III and IV and/or histological FTN (FA,
FC, FVPTC), independently of FNAB cytology. Patients with meta-
static FC or previous thyroid surgery were excluded. All surgeries
were performed in our hospital. FNAB diagnosis was made in our
center and outside. The clinical, FNAB, surgical and pathological
reports and follow-up during 5yrs after surgery were analyzed. The
clinical data evaluatedwere age, gender, cervical palpable mass and
its location, symptoms of cervical compression (hoarseness,
dysphagia, dyspneia and cervical discomfort), thyrotoxicosis and
familial history of thyroid malignancy. FNAB were reclassiﬁed ac-
cording to thyroid cytopathology Bethesda System. Surgical data
included LwI specimen weight and surgical complications (deﬁni-
tive recurrent laryngeal nerve lesion, temporary dysphonia, hypo-
parathyroidism, hematoma/hemorrhage, abscess formation and
keloid scar). Hypothyroidism in LwI group during 5yrs follow-up
was also considered a complication. We also evaluated the reasons
for TC. TC weight was recorded and complications were analyzed as
previously mentioned regarding LwI patients. Pathological features
review focused on macroscopic aspect (capsulated or non-
capsulated), size, uni or multinodular disease, the main histologi-
cal diagnosis and associated lesions, the histological FC invasiveness
and angio-invasiveness, tumor margins and thyroiditis. Outcome at
ﬁve years after surgery included: thyroid nodular relapse, hypo-
thyroidism in LwI group, recurrence ofmalignant pathology (locally
or at distance), and death related to thyroid pathology.
3. Statistical analysis
In few patients’ records there was missing information about
some of the cited topics, so obtained percentages have as denom-
inator the population with valid information. Continuous variables
with normal distribution were expressed in means with standard
deviation and were compared through independent t-Student test.
Those that had not a normal distribution were expressed in me-
dians with interquartile ranges (IQR) and were compared with
ManneWhitney U-test. Categorical variables were presented as
frequency and percentage. They were compared through a Pearson
chi-square test or Fisher exact test. A p value 0.05 was considered
signiﬁcant. ROC curves were employed to deﬁne the best sensitivity
and speciﬁcity cutoff points concerning age and Thyroid-
Stimulating Hormone (TSH) as predictors of malignancy (it was
intended a cutoff point with a speciﬁcity of at least 80%). All sta-
tistical analyses were obtained through Statistical Package for So-
cial Science, version 20.0 (SPSS IBM Corporation).
4. Results
A total of 192 patients were included in this study, 165 females
(85.94%) and 27 males (14.06%). The mean age at diagnosis was
48.61years  14.93 (median 49,0yrs; range 14e80). Nodule
occurred on the right lobe in 57.37% patients, and was palpable
76.87%. Compressive symptoms were reported in 33.65% patients.
LwI median weight was 13.00 g (IQR 12.00 g, range 3.50e111.00 g).
A histological solitary nodule was reported in 118 patients (61.46%)
while 74 (38.54%) hadmultiple nodular lesions. Nodule sizewas not
registered in 4 patients. The remaining 188 patients had a median
histological nodule size of 1.70 cm (IQR 1.70 cm); 33 patients
(17.55%) had an less than 1 cm nodule, 71 patients (37.77%) with 1e
Table 2
Cytological diagnosis (Bethesda Classiﬁcation System for thyroid cytopathology).
FNABa N (%) Malignancy in
histology N (%)
I 9 (4.79%) e
II 25 (13.30%) e
III 26 (13.83%) 9 (34.61%)
IV 105 (55.85%) 43 (40.95%)
V 23 (12.23%) e
Total 188b
a Reclassiﬁcation based on Bethesda classiﬁcation system (FNAB I, II and V were
included because histological study revealed a FTN).
b In four patients, the results of FNAB were unknown.
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(12.77%) being  4 cm.
All patients underwent LwI and 80 (41.67%) required a TC with
median time to completion surgery being 96 days (IQR 52; range
15e1434). TC were required by index lesion’s malignancy [77 pa-
tients (40.10%)], a benign index lesion associated malignant diag-
nosis [2 patients (1.04%)] and by nodular benign relapse in 1 patient
(0.52%) with benign index lesion. TC weight medianwas 7.15 g (IQR
4.00 g, range 1.00e24.00 g). Pathological analysis is explained on
Table 1. Excluding microcarcinomas, 75 (39.06%) of index lesions
were malignant. Surgical margins in malignant lesions were clas-
siﬁed as R0 in 68 out of 73 patients (93.15%) and R1 in 5 (6.85%).
Vascular invasionwas found in 12 out of 75 carcinomas (16.00%). All
patients with R1 borders and/or vascular invasion underwent TC.
Thyroiditis identiﬁed was in 97 out of 180 patients (53.89%). His-
tological evaluation from TC specimen was “normal” in 19 patients
(23.75%), benign in 30 (37.50%) and malignant in 31 (38.75%) e 22
(27.50%) being microcarcinomas. In the 192 patients, concerning
other diagnosis besides index lesion in LwI and TC specimens, 48
(25.00%) presented an incidental papillary microcarcinomas (30 in
LwI and 22 in TC specimen e in 4 patients it was detected in both
LwI and in TC specimens). TSH pre-surgical value was higher in
patients with malignant diagnosis (median in malignant 1.50, IQR
0.10; median in benign 1.30, IQR 1.19; p ¼ 0.027), with malignancy
being less frequent in patients with thyrotoxicosis (p ¼ 0.015).
Histological multinodular pathology was signiﬁcantly associated
with malignancy (p ¼ 0.001). It was not found a statistical signiﬁ-
cant difference concerning all others clinical and pathological fea-
tures evaluated. Patients FNAB re-classiﬁcation is listed on Table 2.
Excluding microcarcinomas in index nodule, 23.08% from Bethesda
category III and 33.33% from category IV weremalignant. Therewas
not a signiﬁcant difference between Bethesda categories III or IV
and occurrence of malignancy by histology. In patients withTable 3
Surgical complications.
LwI complicationsa TC complicationsb
Permanent RLNc lesion 1 (0.58%) Permanent RLN lesion 1 (1.52%)
Temporary dysphonia 16 (9.25%) Temporary dysphonia 4 (6.06%)
Hematoma/Hemorrhage 4 (2.31%) Temporary
hypoparathyroidism
2 (3.03%)






a Unknown in 19 patients.
b Unknown in 14 patients.
c RLN e Recurrent laryngeal nerve.
d Isolated hypothyroidism occurred in 36 (20.81%) patients and 4 patients had
another associated LwI complication (3 an acute and in 1 a late onset complication).Bethesda category IV, a malignant diagnosis was more frequent at
lower age (mean benign 51.81 yrs  13.66; mean malign 44.72
yrs  15.92; p ¼ 0.016) and higher pre-operative TSH (median in
benign 1.19, IQR 0.86; median in malign 1.56, IQR 1.45; p ¼ 0.045).
No statistical signiﬁcant difference was found regarding all others
clinical and pathological features evaluated. In patients with
Bethesda category III, older age was associated with malignancy
(mean benign 44.94 yrs  11.03; mean malign 61.78 yrs  12.43;
p ¼ 0.002). No statistical signiﬁcant difference was found con-
cerning all others clinical and pathological features evaluated.
An TSH pre-operatory value higher than 2.16 mU/L [sensitivity
28.60%; speciﬁcity 79.7%; Area Under the Curve (AUC) 0.615, 95%
Conﬁdence Interval (CI95%): 0.52e0.71] and, in Bethesda category IV,
age lesser than 39.5yrs (sensitivity 37.20%; speciﬁcity 79.00%; AUC
0.63; CI95%: 0.26e0.48) were associated with a malignant diagnosis.
Surgical complications are listed on Table 3. Isolated LwI im-
mediate complications occurred in 19 patients; late onset compli-
cations during follow-up (keloid scar and hypothyroidism)
occurred in 38 patients and 3 patients had both immediate and late
onset complications (hypothyroidism). A nodular relapse in LwI
group was observed in 22 LwI group patients (56.41%) out of 39
who, despite a benign diagnosis, were followed in our center. One
additional patient required TC by benign relapse during follow-up.
In LwI group, 40 patients (36.70%) out of 109 patients developed
hypothyroidism, with higher pre-operatory TSH value (p ¼ 0.011)
being associated to a higher post-operatory hypothyroidism risk.
No malignant thyroid disease relapse was notiﬁed in any patient
nor death for thyroidal disease.
5. Discussion
FTN malignancy rate has been reported to be lesser than 30%,7
however preoperative identiﬁcation and surgical management
remain controversial. Globally, we found a higher malignancy rate
of 45.83%. Excluding incidental microcarcinomas, FNAB III and IV
categories presented values slightly higher (23.08% and 33.33%
respectively) than those predicted according to thyroid cytopa-
thology Bethesda system.7 Other studies have also found higher
malignancy frequencies. Baloch ZW et al. found 31% malignancy
rate in 122 patients who underwent thyroid surgery for FTN6 and
Kim ES found a malignancy rate, in 215 patients, of 47.9%.22 We
veriﬁed that incidental microcarcinomas were prevalent (25% of
patients). Despite papillary microcarcinomas not being an indica-
tion to TT, since they are indolent and 99% are cured by LwI, rarely
their presentation is a metastasis.23 Several malignancy associated
risk factors have been described, including younger age, male
gender, larger nodule size, ultrasonography characteristics and
higher tireoglobuline levels.24e28 Nonetheless, this has not being
uniformly reported in all studies. In our series, only higher TSH
values, no thyrotoxicosis, histological multinodularity and, in
Bethesda IV, lower age were associated with malignancy.
Spanheimer PM et al. found that 18.81% patients who under-
went thyroid LwI required completion surgery and that 42.2%
required opotheraphy,29 so, in this series, LwI could be considered
as an inappropriate approach or without functional beneﬁts in
61.01% of patients. In our study, TC was required in a high propor-
tion of patients (41.67%), mainly by malignant disease in index
nodule or as associated lesions. Besides, in LwI group, 35.78% pa-
tients presented hypothyroidism during follow-up, which corre-
sponds to 23.12% from initial populationwhose complications were
registered. So, we can consider that LwI was inappropriate or
without functional beneﬁt in 64.79% of patients whichmay support
a more extensive approach such as TT. Additionally, we observed a
nodular relapse of at least 20.35% (23/113) during 5 year follow-up
period, and if all patients had been followed, a higher rate would be
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occur in almost all patients until 30 years after initial diagnosis
which could justify follow-up for all patients, including those with
benign diagnosis. Yet, despite this high rate of nodular relapse,
most patients will not need TC.
Rosato et al. followed 14,934 patients during 5 years and
concluded that LwI is the safest thyroidal surgery with a lower
morbidity when compared with TT.30 We found similar rates in LwI
complications as Rosato, except temporary dysphonia which was
higher in our series. Despite LwI being the safest surgical proce-
dure, we found a high TC requirement rate and a relatively low
morbidity increment. Vaiman et al. veriﬁed that, in multinodular
goiter, complications occurrence rate was higher when LwI were
combined with completion surgery versus LwI only, but no statis-
tical signiﬁcant difference in complications occurrence among TT
and lesser invasive approaches.31
In summary, high rate of malignancy and completion surgery
requirement were observed in our patients with FTN as long as
post-LwI hypothyroidism which made LwI inappropriate or
without functional beneﬁt in a signiﬁcant amount of patients.
Additionally, LwI is associated to a higher economical burden in
management the remnant lobe and complications occurrence is not
different between this approach and TT. We propose total thy-
roidectomy as the initial approach for patients with FTN with
preoperative TSH higher than 2.16mU/L and, in Bethesda category
IV, less than 39.5yrs. More studies are required to ﬁnd preoperative
criteria to identify malignancy on FTN. The increase of preoperative
sensitivity, reducing second surgery need, depends on the selection
of the nodule (s) to be biopsied, expertise of cytopathologists and,
hopefully, the introduction of new molecular studies in routine
clinical practice.
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